Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119560 · ClinicalTrials.gov registry record
Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])
A clinical trial, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 576
- Enrollment target
NCT01119560: Completed study, sponsored by Children's Oncology Group.
NCT01119560 is a clinical trial that has completed, run by Children's Oncology Group. The registered enrollment target is 576 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01119560 has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 576 participants
- Enrollment target
Study Summary
This research trial studies the genes biomarkers in children with neuroblastoma. Studying the genes in a child's cancer cells may help doctors improve ways to diagnose and treat children with neuroblastoma.
Primary Outcome
The distributions of the estimated dietary and vitamin intake will be assessed and categories defined using quantiles and confirmation by nonparametric splines. Evaluated under a recessive or log-additive transmission model.
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- OTHER Cytology Specimen Collection Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 576 participants |
| Start Date | 2009-02-03 |
| Est. Completion | 2018-12-31 |
What the finished NCT01119560 record still lists
NCT01119560 is an observational study that tracks outcomes without assigning an intervention. The registered 576 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01119560 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01119560 about?
NCT01119560 is a clinical study titled "Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA])". This research trial studies the genes biomarkers in children with neuroblastoma. Studying the genes in a child's cancer cells may help doctors improve ways to diagnose and treat children with neuroblastoma.
What is the current status of trial NCT01119560?
This trial is currently completed. The enrollment target is 576 participants. The study started on 2009-02-03. Estimated completion is 2018-12-31.
What interventions are being tested in trial NCT01119560?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Cytology Specimen Collection Procedure (OTHER).
Who is sponsoring clinical trial NCT01119560?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04931810 · 576 participants · NA
Urban and Reservation Implementation of All Nations Breath of Life
- NCT05179369 · 576 participants · NA
Well-Mama Community Doula Navigator Study
- NCT06398509 · 576 participants · NA
A Primary Care Based Intervention to Prevent Childhood Obesity Among Low-income Latino Children
- NCT02610439 · 575 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI